Portage Biotech Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alexander Pickett
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Craigmuir Chambers Tortola Virgin Islands, British VG1110
- IPO Date
- Jan 2, 2002
- CIK
- 0001095435
- Website
- portagebiotech.com
- Similar Companies
- Business
- Portage Biotech Inc. is a clinical-stage immuno-oncology company specializing in developing therapies that target checkpoint resistance pathways in cancer. The company's core product portfolio includes small molecule adenosine receptor inhibitors (PORT-6, PORT-7, PORT-8, and PORT-9) focused on selectively blocking A2A and A2B adenosine receptors to enhance anti-tumor immune responses. Additional key programs include invariant natural killer T-cell (iNKT) cell engagers and liposomal iNKT agonists targeting solid tumors and immunogenic pathways. Portage also develops immunomodulatory and adjuvant therapies such as PORT-2 for ocular diseases and PORT-3 as a small molecule cancer vaccine adjuvant. Its research platforms address multiple cancer resistance pathways through various molecular candidates, with active trials in immuno-oncology and potential applications in broader indications. Founded in 2008 and headquartered in Westport, Connecticut, Portage operates primarily in the United States and Canada while leveraging partnerships with pharmaceutical companies and research institutions globally. The company maintains strategic collaborations with entities including Merck & Co., Bristol Myers Squibb, MD Anderson Cancer Center, and University of Toronto, supporting clinical trials and precision medicine development. Recent major developments include a stock-for-stock exchange agreement with Compedica Holdings Limited to support commercialization of the OptiPulse device for diabetic foot ulcers, expanding Portage's footprint in chronic wound care. It has resumed dose escalation cohorts in its ongoing ADPORT-601 Phase 1b clinical trial combining PORT-6 and PORT-7, aiming for first-in-human trials of PORT-7, marking the first combination of selective A2A and A2B antagonists in cancer patients. Additionally, Portage re-launched its wholly-owned subsidiary as Cyncado Therapeutics focusing exclusively on adenosine receptor antagonists, with new leadership appointed to drive external financing and clinical advancement. In 2024, Portage also entered an agreement to sell its iOx Therapeutics subsidiary to Immunova, which includes its liposomal iNKT agonists, to maximize asset value and shareholder returns while continuing collaborations with Immunova. Overall, Portage Biotech positions itself as a pioneer in immuno-oncology with a diversified pipeline targeting tumor microenvironment resistance mechanisms, strategic alliances with major pharma, and ongoing clinical programs that transition its scientific innovations toward therapeutic commercialization.
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
Portage Biotech and Compedica Stock-for-Stock Exchange
Portage Biotech Stock Surges As It Prepares For Human Trial
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Why Is Portage Biotech Stock Skyrocketing Friday?
Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
Portage Biotech Announces Completion of $2.15 Million Private Financing
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Portage Biotech Reports Business and Strategic Update
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update